JW Pharmaceutical announced on May 12 that the results of phase 1a clinical trials (single dose) on CWP291, a candidate material for acute myeloid leukemia (AML), has been published in the online edition of Blood Advances, a journal published by the American Society of Hematology (ASH).
CWP291 is a targeted anticancer agent that suppresses Wnt/β-catenin, a signaling substance affecting cancer cell growth and cancer stem cells. It is a first-in-class new drug candidate being developed for various carcinomas such as acute myelogenous leukemia, multiple myeloma, and stomach cancer.
The study is the results of research conducted by JW Pharmaceutical in the United States and Korea from September 2011 to December 2015.
The clinical trial was conducted to determine a maximum tolerated dose while confirming the safety of CWP291 starting from a 4mg/㎡ dose.
Of the 54 patients with acute myeloid leukemia who could be evaluated according to the strict criteria of the International Working Group for AML and MDS, one was confirmed to be in complete remission (CR) with cancer cells annihilated and another patient was found to be in partial remission ( PR).
JW Pharmaceutical has a library of 25,000 kinds of compounds that mimic the structures of proteins capable of controlling biological phenomena. It also has the JWELRY System, an anticancer drug screening system consisting of various cancer cell panels that interpret genomic information, and the High-Speed Screening System (HTS) that selects compounds that act on Wnt signal pathways.